BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 29673279)

  • 1. Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.
    Hou S; Tiriac H; Sridharan BP; Scampavia L; Madoux F; Seldin J; Souza GR; Watson D; Tuveson D; Spicer TP
    SLAS Discov; 2018 Jul; 23(6):574-584. PubMed ID: 29673279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for high throughput 3D drug screening of patient derived melanoma and renal cell carcinoma.
    Ortiz Jordan LM; Vega VF; Shumate J; Peles A; Zeiger J; Scampavia L; Spicer TP
    SLAS Discov; 2024 Apr; 29(3):100141. PubMed ID: 38218316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1536-Well 3D Viability Assay to Assess the Cytotoxic Effect of Drugs on Spheroids.
    Madoux F; Tanner A; Vessels M; Willetts L; Hou S; Scampavia L; Spicer TP
    SLAS Discov; 2017 Jun; 22(5):516-524. PubMed ID: 28346088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead identification using 3D models of pancreatic cancer.
    Fernandez-Vega V; Hou S; Plenker D; Tiriac H; Baillargeon P; Shumate J; Scampavia L; Seldin J; Souza GR; Tuveson DA; Spicer TP
    SLAS Discov; 2022 Apr; 27(3):159-166. PubMed ID: 35306207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids.
    Schuster B; Junkin M; Kashaf SS; Romero-Calvo I; Kirby K; Matthews J; Weber CR; Rzhetsky A; White KP; Tay S
    Nat Commun; 2020 Oct; 11(1):5271. PubMed ID: 33077832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening.
    Deben C; De La Hoz EC; Compte ML; Van Schil P; Hendriks JMH; Lauwers P; Yogeswaran SK; Lardon F; Pauwels P; Van Laere S; Bogaerts A; Smits E; Vanlanduit S; Lin A
    Cell Oncol (Dordr); 2023 Apr; 46(2):299-314. PubMed ID: 36508089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
    Burkhart RA; Baker LA; Tiriac H
    Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
    Mebarki M; Bennaceur A; Bonhomme-Faivre L
    Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalizing pancreatic cancer organoids with hPSCs.
    Zhang HC; Kuo CJ
    Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
    [No Abstract]   [Full Text] [Related]  

  • 10. RNAi High-Throughput Screening of Single- and Multi-Cell-Type Tumor Spheroids: A Comprehensive Analysis in Two and Three Dimensions.
    Fu J; Fernandez D; Ferrer M; Titus SA; Buehler E; Lal-Nag MA
    SLAS Discov; 2017 Jun; 22(5):525-536. PubMed ID: 28277887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening.
    Du Y; Li X; Niu Q; Mo X; Qui M; Ma T; Kuo CJ; Fu H
    J Mol Cell Biol; 2020 Aug; 12(8):630-643. PubMed ID: 32678871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids.
    Renner H; Grabos M; Becker KJ; Kagermeier TE; Wu J; Otto M; Peischard S; Zeuschner D; TsyTsyura Y; Disse P; Klingauf J; Leidel SA; Seebohm G; Schöler HR; Bruder JM
    Elife; 2020 Nov; 9():. PubMed ID: 33138918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
    Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
    Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Automated High-Throughput Screening (HTS) Spotter for 3D Tumor Spheroid Formation.
    Jeong MH; Kim I; Park K; Ku B; Lee DW; Park KR; Jeon SY; Kim JE
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening in colorectal cancer tissue-originated spheroids.
    Kondo J; Ekawa T; Endo H; Yamazaki K; Tanaka N; Kukita Y; Okuyama H; Okami J; Imamura F; Ohue M; Kato K; Nomura T; Kohara A; Mori S; Dan S; Inoue M
    Cancer Sci; 2019 Jan; 110(1):345-355. PubMed ID: 30343529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.